
HeartBeam, Inc. (NASDAQ:BEAT – Free Report) – Research analysts at HC Wainwright lifted their FY2026 EPS estimates for HeartBeam in a research report issued to clients and investors on Monday, November 16th. HC Wainwright analyst Y. Chen now forecasts that the medical research company will post earnings per share of ($0.30) for the year, up from their previous estimate of ($0.37). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for HeartBeam’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for HeartBeam’s Q4 2026 earnings at ($0.06) EPS, Q1 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.05) EPS and FY2027 earnings at ($0.22) EPS.
Several other equities analysts have also recently weighed in on BEAT. Wall Street Zen upgraded HeartBeam to a “sell” rating in a report on Saturday, October 10th. Weiss Ratings downgraded shares of HeartBeam from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $4.00.
HeartBeam Trading Down 9.3%
BEAT stock opened at $0.31 on Wednesday. HeartBeam has a 1-year low of $0.30 and a 1-year high of $4.00. The business’s 50-day moving average price is $0.42 and its two-hundred day moving average price is $0.78.
HeartBeam (NASDAQ:BEAT – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The medical research company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.04. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.08 million.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the company. Sigma Planning Corp raised its position in HeartBeam by 115.0% in the 1st quarter. Sigma Planning Corp now owns 132,550 shares of the medical research company’s stock valued at $162,000 after buying an additional 70,900 shares during the last quarter. Beacon Pointe Advisors LLC acquired a new position in HeartBeam during the 2nd quarter worth approximately $185,000. Ritholtz Wealth Management acquired a new position in HeartBeam during the 3rd quarter worth approximately $103,000. Finally, BlackRock Inc. bought a new position in shares of HeartBeam during the 2nd quarter worth approximately $741,000. 7.77% of the stock is currently owned by institutional investors.
About HeartBeam
HeartBeam, Inc. is a medical technology company developing portable cardiac monitoring tools. Its technology is designed to record electrical signals from the heart in three dimensions and use them to create a synthesized 12-lead electrocardiogram (ECG), which can provide clinicians with information about cardiac activity beyond that of a standard single-lead reading. The company’s HeartBeam System combines a compact, cable-free recording device with software for analyzing and presenting ECG data.
Recommended Stories
- Five stocks we like better than HeartBeam
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for HeartBeam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartBeam and related companies with MarketBeat.com's FREE daily email newsletter.
